Our Mission

Launched in 2003, the Kidney Cancer Journal serves as the most comprehensive, peer-reviewed resource of information for physicians on the diagnosis and treatment of renal cell carcinoma and all of its tumor types. Published quarterly and guided by a Medical Advisory Board and an Editorial Advisory Board of leading investigators and thought leaders involved in pivotal clinical trials, the Kidney Cancer Journal and its International Edition focus on the impact of translational research in oncology and urology.

Reviewing new data in the peer-reviewed medical literature, presenting case histories, and evaluating the merits of bench research, the journal offers an in-depth analysis of trends affecting patient care. The Kidney Cancer Journal is the official journal of the Kidney Cancer Association and provides Continuing Medical Education credit in association with City of Hope National Medical Center, Duarte, California. Through its review of manuscript submissions by the Medical Advisory Board and Editorial Advisory Board, the journal seeks to provide the most reliable, authoritative, and scientifically rigorous information available to physicians involved in the management of renal cancer. This audience includes medical oncologists, hematologist-oncologists, and urologists.

With the advisory boards serving as a touchstone for the latest information on new drug development, the journal also alerts its readers to the relevance of ongoing clinical trials, the availability of trial enrollment, the protocols of such research, and the progress made toward the approval of new agents undergoing study. As part of its mission to inform its readership, the journal also reports on data presented at major medical meetings, including the Scientific Sessions of the American Society of Clinical Oncology, the American Urological Association and the International Symposia of the Kidney Cancer Association.

Editor-in-Chief
Robert A. Figlin, MD
Arthur and Rosalie Kaplan Chair in Oncology
Professor and Chair, Medical Oncology and
Therapeutics Research
City of Hope National Medical Center and
Beckman Research Institute
Associate Director for Clinical Research
City of Hope Comprehensive Cancer Center
Duarte, California

Medical Advisory Board
Michael B. Atkins, MD
Deputy Chief, Division of Hematology-Oncology
Director, Cancer Clinical Trials Office
Beth Israel Deaconess Medical Center
Leader, Renal Cancer Program,
Dana Farber Harvard Cancer Center
Boston, Massachusetts

Ronald M. Bukowski, MD
Director, Department of Experimental Therapeutics
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio

Robert J. Motzer, MD
Attending Physician, Memorial Sloan-Kettering
Cancer Center
New York City
Professor of Medicine
Weill Medical College of Cornell University
Ithaca, New York

Walter M. Stadler, MD
Fred C. Buffett Professor
Departments of Medicine and Surgery
Sections of Hematology-Oncology and Urology
University of Chicago Medical Center
Chicago, Illinois

Christopher G. Wood, MD
Associate Professor, Departments of Urology
and Cancer Biology
University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Nurse Advisory Board
Nancy Moldawer, RN, MSN
Nursing Director
City of Hope Kidney Cancer Program
City of Hope Comprehensive Cancer Center
Duarte, California

Laura Wood, RN, MSN, OCN
Renal Cancer Research Coordinator
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio

Patient Advocate
William P. Bro
Chief Executive Officer
Kidney Cancer Association



Publishing Staff
Stu Chapman, Executive Editor
Jenny Chapman, Assoc. Dir, Editorial Services
Frank Iorio, Director of Business Development
Heidi Green, Associate Editor
Gloria Catalano, Production Director
Michael McClain, Design Director

Editorial Offices
160 Cabrini Blvd., Suite 95
New York, NY 10033
Tel: (516) 356-5006

Copyright 2008 Genitourinary Publishing.
All rights reserved. None of the contents may be reproduced in any form without the permission of the publisher.

Arie Belldegrun, MD
David Geffen School of Medicine
at UCLA
Los Angeles, California

Steven Campbell, MD
Cleveland Clinic Foundation
Cleveland, Ohio

Janice P. Dutcher, MD
Our Lady of Mercy Medical Center
Comprehensive Cancer Center
Bronx, New York

Timothy Eisen, MD
Royal Marsden Hospital
London, UK

Paul Elson, PhD
Cleveland Clinic Foundation
Cleveland, Ohio

Bernard Escudier, MD
Institut Gustave-Roussy
Villejuif, France

James H. Finke, PhD
Cleveland Clinic Lerner College of
Medicine of Case Western Reserve
University
Cleveland, Ohio

Keith Flaherty, MD
Abramson Cancer Center of the
University of Pennsylvania
Philadelphia, Pennsylvania

Daniel J. George, MD
Duke Clinical Research Institute
Durham, North Carolina

Martin Gore, MD
Royal Marsden Hospital
London, UK

Gary Hudes, MD
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Thomas Hutson, DO, PharmD
Baylor University Medical Center
Dallas, Texas

Eric Jonasch, MD
University of Texas
MD Anderson Cancer Center
Houston, Texas

Eugene D. Kwon, MD
Mayo Clinic
Rochester, Minnesota

Bradley C. Leibovich, MD
Mayo Clinic
Rochester, Minnesota

Kim A. Margolin, MD
City of Hope National Medical Center
Duarte, California

David Nanus, MD
New York Presbyterian Hospital-
Weill Cornell Medical Center
New York, New York

Andrew C. Novick, MD
Cleveland Clinic Foundation
Cleveland, Ohio

Leslie Oleksowicz, MD
College of Medicine
University of Cincinnati
Medical Center
Cincinnati, Ohio

Allan Pantuck, MD
David Geffen School of Medicine
at UCLA
Los Angeles, California

Brian Rini, MD
Cleveland Clinic Foundation
Cleveland, Ohio

Paul Russo, MD
Memorial Sloan-Kettering
Cancer Center
New York, New York

Ihor S. Saczuk, MD
Hackensack University
Medical Center
Hackensack, New Jersey

Domenic A. Sica, MD
Medical College of Virginia
Richmond, Virginia

Jeffrey A. Sosman, MD
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

David Swanson, MD
University of Texas
MD Anderson Cancer Center
Houston, Texas

Nicholas J. Vogelzang, MD
Nevada Cancer Institute
Las Vegas, Nevada

Editorial Advisory Board